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Abstract
Background: Human embryonic stem cells exhibit genomic instability that can be related to culture duration or to
the passaging methods used for cell dissociation. In order to study the impact of cell dissociation techniques on
human embryonic stem cells genomic instability, we cultured H1 and H9 human embryonic stem cells lines using
mechanical/manual or enzymatic/collagenase-IV dissociation methods. Genomic instability was evaluated at early
(<p60) and late (>p60) passages by using oligonucleotide based array-comparative genomic hybridization 105 K
with a mean resolution of 50 Kb.
Results: DNA variations were mainly located on subtelomeric and pericentromeric regions with sizes <100 Kb.
In this study, 9 recurrent genomic variations were acquired during culture including the well known duplication
20q11.21. When comparing cell dissociation methods, we found no significant differences between DNA variations
number and size, DNA gain or DNA loss frequencies, homozygous loss frequencies and no significant difference on
the content of genes involved in development, cell cycle tumorigenesis and syndrome disease. In addition, we
have never found any malignant tissue in 4 different teratoma representative of the two independent stem cell lines.
Conclusions: These results show that the occurrence of genomic instability in human embryonic stem cells is similar
using mechanical or collagenase IV-based enzymatic cell culture dissociation methods. All the observed genomic
variations have no impact on the development of malignancy.
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Background
Human embryonic stem cells (hESC) are derived from
inner cell mass of blastocyst stage embryos [1]. These
cells exhibit pluripotency and self-renewal properties.
Indeed, hESC can differentiate into the three germlines
that constitute a potential use of the cells in therapeu-
tics, transplantation, drug testing as well as to study
early embryogenesis. Even though it is possible to culti-
vate for a long time hESC and maintain their undifferen-
tiated state the current in vitro culture conditions are
not optimal and still new methods need to be developed.
Previous studies showed that hESC could acquire non-
random genetic changes after prolonged cell passages
affecting cell growth and differentiation potential [2,3].
These genomic variations represent a selection providing
to the cells a strong advantage [4,5]. The accumulation
of chromosomal abnormalities during hESC culture may
be due to decrease efficiency of base excision repair,
surnumerary centrosomes and/or malfunction of the cell
cycle checkpoints [5-8]. Environmental factors may in-
fluence genomic behavior such as culture media, feeder
layer or dissociation methods used for cell passaging.
Impact of cell culture dissociation techniques on gen-
omic instability in particular enzymatic based-methods
was underlined by many authors [2,9-15]. Others studies
observed chromosomal integrity when mechanical/man-
ual dissociation was used [16-18]. However, these studies
were based on conventional cytogenetic techniques allow-
ing a chromosomal study with a resolution of 10 Mb.
Some authors combined these assays with chromosome
based-comparative genomic hybridization (classic CGH)
allowing an overview of the whole genome for the detec-
tion of DNA copy changes. But, similarly to the karyotype,
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resolution of classic CGH may not allow detection of
genomic variations smaller than 10 Mb.
Recently, studies on hESC genomic instability were
obtained using microarray-based comparative genomic
hybridization (array-CGH) or single nucleotide polymor-
phisms (SNP) array allowing a high resolution chromo-
somal study under 100 Kb [19-22]. Nevertheless, the
effects of passaging culture methods on genomic in-
stability were not investigated using array-CGH.
In this study, we carried out an extensive molecular
cytogenetic analysis on two hESC lines H1 and H9 cul-
tured beyond 60 passages on mouse embryonic fibro-
blasts (MEF) and passaged by mechanical or collagenase
IV-based enzymatic methods. We used array-CGH with
a mean resolution of 50 Kb to uncover subkaryotypic
genome alterations and subsequent gene content. Tera-
toma formation potency was realized in order to assess
the functional impact of the dissociation methods used.
Results
Analysis of pluripotent markers expression across the time
During the successive cell passages, the hESC lines
showed no morphological evolution that may indicate
that they had lost their pluripotent status. However, to
ensure their pluripotent state, we performed an expres-
sion analysis of three specific markers of pluripotence
(HESCA, SSEA-4 and TRA 1–60) at early (<p60) and
late (>p60) passages (Additional file 1: Figure S1). In all
cases, we observed an extreme stability of expression of
these three markers between early and late passages
(Additional file 1: Figure S1). These results confirmed
the maintenance of the pluripotent state of these cells
during this study.
Analysis of H1 and H9 hESC lines by conventional
cytogenetic and FISH analysis
A systematic chromosomal assay using karyotype and FISH
was realized at regular passages for the two cell lines H1
and H9 using both passaging methods (Additional file 2:
Table S5). Analysis for H1 cell lines showed a normal
male karyotype 46,XY (Additional file 3: Figure S2A).
Similarly, H9 cell lines showed normal female karyotype
46,XX (Additional file 3: Figure S2B).
The centromeric probes specific for chromosomes 12 and
17 showed normal hybridization excluding chromosomes
12 and 17 aneuploidies. BACs RP5-1018D12 and RP3-
324O17 hybridization gave one signal on both chromo-
somes 20 thus excluding the recurrent 20q11.2 duplication.
Global characterization of genomic instability by
array-CGH in H1 and H9 hESC lines
First we analyzed array-CGH results considering all gen-
omic variations i.e. including polymorphic DNA variations
described in Toronto Database of Genomic Variants
(http://projects.tcag.ca/cgi-bin/variation/gbrowse/hg18/).
Individual representation of genomic variations of the two
hESC lines is shown in Figure 1. We observed that the
genomic variations were mainly located on subtelomeric
and pericentromeric regions.
Table 1 mentions 9 recurrent DNA variations occur-
ring during culture of the hESC lines. These genomic
variations are described according to chromosomal
position, size, gene content and type (gain/loss). We
observed that more than half-variations (6/9) carried
relevant genes involved in development, cell cycle,
growth, apoptosis, tumorigenesis and/or syndrome/
disease (Table 1). An example of plots of the 1q21.3
region is presented in Additional file 4: Figure S3.
Detailed characteristics of total genomic variations
comparing early (<p60) manual, early enzymatic (<p60)
and late enzymatic (>p60) passages are shown in Figure 2.
Results are presented as mean of the two cell lines (early
manual passages, H1p56, H9p30; early enzymatic passages,
H1p56, H9p30; late enzymatic passages, H1p159, H9p87).
Total number of genomic variations was stable after
enzymatic technique (13.50 ± 3.88) compared to manual
technique (12.00 ± 2.12) at early passages; and increased by
about 3-fold after late enzymatic passages (42.00 ± 23.33)
compared to early enzymatic passages (13.50 ± 3.88) but
were not significantly different (Figure 2A). There were no
significant differences between the percentages of DNA
losses or DNA gains between early manual and early
enzymatic passages (loss, 60.00 ± 18.85% versus 45.39 ±
20.93%; gain, 40.00 ± 18.85% versus 54.60 ± 20.93%) and
between early and late enzymatic passages (loss, 45.39 ±
20.93% versus 77.33 ± 7.54%; gain, 54.60 ± 20.93% versus
22.66 ± 7.54%) (Figure 2B). The percentages of homozy-
gous copy loss were not significantly different between
both cell dissociation methods at early passages (early
manual, 56.41 ± 7.25%; early enzymatic, 41.66 ± 17.67%)
and between enzymatic passages (early enzymatic, 41.66 ±
17.67%; late enzymatic, 32.57 ± 0.53%) (Figure 2C).
When looking at the size of the variations, we ob-
served no significant differences between early manual
and early enzymatic passages or early enzymatic and late
enzymatic passages (Figure 2D). However, for each
group small genomic variations <100 Kb were more im-
portantly observed than intermediate genomic variations
(100 Kb-1 Mb) and than large genomic variations
(>1 Mb) (Figure 2D). Indeed, for early manual group
small genomic variations were about 3-fold higher than
intermediate genomic variations (67.77 ± 8.64% versus
23.33 ± 7.07%) and by about 7.5-fold higher than large
genomic variations (67.77 ± 8.64% versus 8.88 ± 5.97%)
(Figure 2D). For early enzymatic group, small variations
were about 6.5-fold higher than intermediate variations
(81.25 ± 13.25% versus 12.50 ± 8.83%) and by about 13-
fold higher than large variations (81.25 ± 13.25% versus
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Figure 1 Array-CGH DNA variations distribution. Individual distribution of total chromosomal aberrations for H1 (A) and H9 (B) hESC cell lines
including polymorphic CNVs described in Toronto Database of Genomic Variants. Each bar represented one genomic variation: green, gain; red, loss.
Table 1 Recurrent genomic variations acquired during hESC H1 and H9 culture
Chromosome
region












1q21.3 12.42-25.84 LCE3C4 L - L G - G
4p16.3 27.74-253.75 FAM53A - - - - G L
6p21.32 37.12-81.43 HLA-DRB54 L L L G G G
11q11 54.62-82.97 OR4C11, OR4P4, OR4S2 L L L L - L
14q23.2 295.35 KCNH5, RHOJ3, GPHB5 - - - G - G
14q23.3 398.69 FUT83 - - - G - G
15q11.2 1270.33-1779-68 LOC283755, A26B1, OR4M2, OR4N4, LOC650137 L L L G - G
20q11.21 1022.42 DEFB115-116,118-119,121,123-124, REM1, HM13,
ID12, COX4I24, BCL2L12
- - G - - -
22q13.2 17.66 SCUBE11 - - - - - L
Recurrent genomic variations observed during hESC lines H1 and H9 in vitro culture using manual or enzymatic techniques. Chromosomal region, minimal/maximal
sizes, common genes and variation type (loss/gain) are mentioned. E, enzymatic passages; G, gain; L, loss; M, manual passages; max, maximal; min, minimal; 1, genes
related to development; 2, genes related to cell cycle, growth and apoptosis; 3, genes related to tumorigenesis; 4, genes related to syndrome and disease.
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6.25 ± 4.41%) (Figure 2D). For late enzymatic group,
small variations were about 4.5-fold higher than inter-
mediate variations (70.44 ± 10.52% versus 15.77 ± 1.76%)
and by about 5-fold higher than large variations (70.44 ±
10.52% versus 13.77 ± 5.97%) (Figure 2D).
Total number of genes included in genomic variations
was not significantly different between early manual and
early enzymatic passages (64.00 ± 3.53 and 47.00 ± 9.19,
respectively) and between early enzymatic and late
enzymatic passages (47.00 ± 9.19 and 210.5 ± 86.62, re-
spectively) (Figure 2E). The number of miRNA included
in genomic variations was quite similar between early
manual (1.00 ± 0.00) and early enzymatic (0.50 ± 0.35)
methods; and between early (0.50 ± 0.35) and late (3.50
± 1.06) enzymatic methods (Figure 2E).
Characterization of genomic variations without polymorphic
CNVs by array-CGH of H1 and H9 hESC cell lines
Secondly, we interpreted array-CGH results without
polymorphic variants described in Toronto Database of
Genomic Variants. The content of this database is only
representing structural variation identified in healthy
control samples. Thus remaining DNA variation can be
interpreted as potentially pathogenic or of unknown
signification. Comparison between early manual (<p60),
early enzymatic (<p60) and late enzymatic (>p60) pas-
sages is shown in Figure 3. Results are presented as
mean of the two cell lines (early manual passages,
H1p56, H9p30; early enzymatic passages, H1p56, H9p30;
late enzymatic passages, H1p159, H9p87).
Concerning the size of DNA variations, we did not
observe significant differences between early manual
and early enzymatic methods for small genomic varia-
tions <100 Kb (67.85 ± 12.62% versus 83.33 ± 11.78%),
intermediate genomic variations 100 Kb-1 Mb (32.14 ±
12.62% versus 16.66 ± 11.78%) and large genomic varia-
tions (0.00 ± 0.00% versus 0.00 ± 0.00%) (Figure 3A).
Similarly, we did not observe significant differences
between early enzymatic and late enzymatic methods
for small (83.33 ± 11.78% versus 62.93 ± 9.14%),
Figure 2 array-CGH DNA variations including polymorphisms at early manual, early enzymatic and late enzymatic passages. Comparison of
genomic variations including polymorphic CNVs. Results are presented as mean of the two cell lines (early manual passages, H1p56, H9p30; early
enzymatic passages, H1p56, H9p30; late enzymatic passages, H1p159, H9p87). The criteria evaluated were total number of variations (A), variation
type (gain/loss) (B), homozygous loss percentage (C), variation size (<100 Kb, 100 Kb-1 Mb, >1 Mb) (D), and total number of genes and miRNA (E).
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intermediate (16.66 ± 11.78% versus 10.34 ± 7.31%) and
large (0.00 ± 0.00% versus 26.72 ± 16.46%) genomic
variations (Figure 3A). However, for each group varia-
tions <100 Kb were more importantly observed. In-
deed, for early manual group, small variations were
about 2-fold higher than intermediate variations
(67.85 ± 12.62% versus 32.14 ± 12.62%) and higher than
large variations (67.85 ± 12.62% versus 0.00 ± 0.00%, P =
0.06) (Figure 3A). For early enzymatic group, small varia-
tions were about 5-fold higher than intermediate varia-
tions (83.33 ± 11.78% versus 16.66 ± 11.78%) and higher
than large variations (83.33 ± 11.78% versus 0.00 ± 0.00%)
(Figure 3A). For late enzymatic group, small variations
were about 6-fold higher than intermediate variations
(62.93 ± 9.14% versus 10.34 ± 7.31%) and by about 4-fold
higher than large variations (62.93 ± 9.14% versus 26.72 ±
16.46%) (Figure 3A).
For genes carried by genomic variations, we did not
observe significant increase of gene number in early en-
zymatic group versus early manual group independently
of what the gene functions are (development, 1.00 ± 0.70
versus 0.50 ± 0.35; cell cycle/growth/apoptosis, 1.00 ±
0.70 versus 1.00 ± 0.00; tumorigenesis, 5.00 ± 2.82 versus
2.50 ± 0.35; syndrome disease 1.00 ± 0.00 versus 0.00 ±
0.00); nor in late enzymatic versus early enzymatic
groups (development, 1.50 ± 0.35 versus 1.00 ± 0.70; cell
cycle/growth/apoptosis, 2.50 ± 0.35 versus 1.00 ± 0.70;
tumorigenesis, 3.00 ± 2.12 versus 5.00 ± 2.82; syndrome
disease 1.50 ± 1.06 versus 1.003 ± 0.00) (Figure 4B). The list
of genes involved in development; cell cycle, growth and
apoptosis; tumorigenesis; and syndrome and disease are
presented in Additional file 5: Table S1, Additional file 6:
Table S2, Additional file 7: Table S3 and Additional file 8
Table S4, respectively.
When looking at tumorigenesis genes, we did not
observe differences between early enzymatic versus early
manual groups for total number of oncogenes, of tumor
suppressor genes or of other genes like fusion genes
(oncogenes, 2.50 ± 1.06 versus 1.50 ± 0.35; tumor suppres-
sor genes, 1.00 ± 0.70 versus 2.00 ± 1.41; others, 0.50 ± 0.35
versus 0.00 ± 0.00); nor between late enzymatic versus early
enzymatic groups (oncogenes, 1.50 ± 1.06 versus 2.50 ±
1.06; tumor suppressor genes, 1.00 ± 0.70 versus 2.00 ±
1.41; others, 0.50 ± 0.35 versus 0.50 ± 0.35) (Figure 4C, left
panel). Similarly, the percentage of oncogenes gain and the
percentage of tumor suppressor genes loss were not differ-
ent between early enzymatic versus early manual groups
(75.00 ± 17.67% versus 100.00 ± 0.00% and 12.50 ± 8.83 ver-
sus 50.00 ± 35.35, respectively) nor between late versus
early enzymatic groups (33.33 ± 23.57% versus 75.00 ±
17.67% and 50.00 ± 35.35 versus 12.50 ± 8.83, respectively)
(Figure 4C, right panel).
Figure 3 Array-CGH DNA variations without polymorphisms at early manual, early enzymatic and late enzymatic passages. Comparison of
genomic variations excluding polymorphic CNVs. Results are presented as mean of the two cell lines (early manual passages, H1p56, H9p30;
early enzymatic passages, H1p56, H9p30; late enzymatic passages, H1p159, H9p87). The criteria evaluated were variation size (A), gene content
distributed in 4 groups according to their function: development, cell cycle/growth/apoptosis, tumorigenesis and syndrome/disease (B), and
tumorigenesis gene characteristics (C).
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Evaluation of the differentiation potential of H1 and H9
cell lines in vivo
Teratoma-forming potential and tumor content by
histological analysis were explored in the H1 and H9 cell
lines. This teratoma assay enabled clear-cut evaluation
of the impact of both dissociation protocols on the
behaviour, the differentiation and the proliferation of
hESCs in vivo over a period of several months. Further-
more, the teratoma assay is the only test that may reveal
the tumoral potential linked with hESC that have ac-
quired genome alterations and specially genes involved
in tumorigenesis or in specific syndrome and disease.
For the teratoma assay, 2 to 3x106 cells were picked at
early (p38/p40/p44) and late (p63) passages were
injected intramuscularly. For H1 and H9 the two dissoci-
ation protocols were compared (Figure 4A). All four
hESC produced teratomas after 96 to 160 days. Histo-
logical analysis showed a differentiation into ectodermal,
endodermal and mesodermal tissues, mainly represented
by glial tissues, glandular epitheliums and large cartil-
aginous areas, respectively (Figure 4B). All the structures
observed showed mature and well differentiated tissues
without malignancy. Furthermore all teratomas were
negative for Ki-1 antigen (CD30) (data not shown) which
is highly predictive of pluripotent stem cells-derived ma-
lignancies [23], confirming the absence of any embryonic
malignant tissues.
In conclusion, for the two hESC lines H1 and H9,
global genomic variations including polymorphisms were
particularly observed in subtelomeric and pericentro-
meric regions and were mainly of small size (<100 Kb).
The use of collagenase IV did not induced significant
differences. When excluding polymorphic genomic vari-
ations during data interpretation, we found no effect on
gene content neither between early manual versus early
enzymatic passages nor between early enzymatic versus
late enzymatic passages. Furthermore, both protocols
had no functional effect on in vivo malignancy as dem-
onstrated by teratoma assays.
Discussion
Our results showed that during short and long term
culture of the hESC H1 and H9, DNA variations were
mostly located on instable regions of the genome such
Figure 4 Germ cell layers components within teratomas. Differentiation of H1 and H9 (picked at different passages and dissociated by manual or
enzymatic protocols) into ectoderm, endoderm and mesoderm was quantified using whole section Hematoxylin and eosin stains (A). All lines
showed structures representing the 3 lineages (ectoderm, endoderm and mesoderm) and were scored as follows: “ - ” indicating the absence of
the tissue; “ + ” and “ ++ ” indicating the existence of differentiated tissues that were respectively moderately (one to 5 focus) or highly (>5 focus)
represented. Characteristics of hESC-derived teratomas (B): a, b, c; Hematoxylin and eosin staining of teratoma derived from H1 (passage 63 and
treated with enzymatic dissociation). d; Cytokeratin AE1/AE3 immunostaining of teratoma derived from H1 showing epithelial structures. e; Hematoxylin
and eosin staining of teratoma derived from H9 (passage 40 and treated with enzymatic dissociation). N, neural tissue (ectoderm); C, cartilage
(mesoderm); Ep, keratin-containing epidermal tissue (ectoderm); M, striated muscle (mesoderm); B, bone (mesoderm); E, gut epithelial tissue (endoderm).
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as subtelomeric and pericentromeric regions. In our
study, the use of collagenase IV for cell dissociation did
not induce significant changes on genes carried by these
genomic variations in comparison with mechanical cell
passages.
Genomic variations include single nucleotide polymor-
phisms (SNP), insertions/duplications, deletions and
inversions/translocation. Variability of copy number
variation (CNV) is estimated to 10-20% of the human
genome ([24,25], Database of Genomic Variants http://
projects.tcag.ca/cgi-bin/variation/gbrowse/hg18/). The gen-
omic variations are considerated as either polymorphic
(or benign, currently referenced in Toronto database of
genomic variants), of unknown signification or patho-
genic. In our study, we found a mean of twenty-four
CNV per hESC line analyzed. The size of CNV ranged
from 0.4 Kb to 3.155 Mb, i.e. undetectable using stand-
ard karyotype analysis (mean resolution of 10 Mb). We
found more small genomic changes (<100Kb) than
intermediate (100 Kb-1 Mb) and large (>1 Mb) ones.
Larger genomic changes have a greater chance of con-
ferring a negative advantage, and of being selected out.
We observed that DNA variations were carried by in-
stable regions of the genome such as subtelomeric and
pericentromeric regions. Subtelomeric and pericentro-
meric regions are dynamic chromosomal regions carry-
ing repetitive elements. Other chromosomal regions are
considered instable in relation to the architecture of the
genome as segmental duplications. These particular
conformations of DNA favor deletion and duplication
aberrations. Pathogenic CNV may affect gene expression
and may influence phenotypic variation by disrupting
genes and altering dosage compensation. Thus, DNA copy
variations may influence replication/proliferation, differen-
tiation and functional potentials of human ESC.
In the past few years, several authors reported contro-
versial results on genomic integrity during prolonged
in vitro hESC culture [2,3,11-16,26-29]. These results
may be dependent on the passaging methods used, on
the use or not of feeders or on the duration of the cul-
ture. Indeed, according to in vitro culture systems, se-
lective pressures from the environment may influence
genomic stability. However, genomic stability of hESC
lines is essential for maintaining cell properties [30].
Some studies on hESC genomic instability using array-
CGH or SNP array were recently published however the
effect of passaging method was not investigated [19-21].
It is important to distinguish random and nonrandom
DNA variations. Nonrandom acquired somatic muta-
tions reflect a selective advantage independent of culture
conditions. Genomic changes affecting others regions
might be more likely to depend upon culture conditions.
The International Stem Cell Initiative consortium ob-
served a large differential in frequency between gain and
loss of chromosomes, gains being more frequent [20].
Aberrations are located in all chromosomes except
chromosome 4 [20]. Some abnormalities such as gain of
chromosome 12 (presence of the pluripotency NANOG
gene and the cell-cycle regulator CCND2 in 12p13; the
oncogene KRAS in 12p12.1), chromosome 17 (BIRC5
candidate gene in 17q25, an antiapoptotic gene associ-
ated with the highest-risk tumor), chromosome 20 and
chromosome X or fragments of these chromosomes may
promote self-renewal and thus provide a selective prolif-
erative/survival advantage [3,31,32]. Nonrandom abnor-
malities revealed culture adaptation of human ES as
suggested by the ISCI consortium study [20]. ISCI meta-
analysis revealed a recurrent loss in 22q13-qter region,
as a novel finding. In contrast, other karyotypic abnor-
malities result in no effect or delayed cell cycle and pro-
liferation rate.
Recurrent genomic variations, as illustrated in Table 1,
were observed in the two unrelated hESC lines. This
observation suggests that some specific chromosomal
regions confer a selective advantage to the cells during
in vitro culture. In accordance with published results, we
found recurrent gain of 1q21, 20q11.2 and loss of 22q13
regions (Table 1) [4,5,20,31-35]. These three chromo-
somal regions harbored genes of particular importance
for culture adaptation like LCE3C (involved in barrier
repair after injury or inflammation, 1q21.3; [36]),
BCL2L1 (regulates cell survival and death, 20q11.21;
[37]) and SCUBE1 (roles in development, inflammation
and thrombosis, 22q13.2; [38]). We found that copy
number variation (deletion or duplication) of the
6p21.32 region was systematically detected. The minimal
region included the HLA-DRB5 gene, coding for HLA
class II beta chain paralogues. The HLA-DRB5 gene is
involved in genetic susceptibility to multiple sclerosis
(MS) as HLA-DRB5 null subjects appear to be at increased
risk for developing secondary progressive MS [39]. Wu
and colleagues also described a deletion 6p21.32 of 40 Kb
including this gene in HSF1 and HSF6 hESC lines using
244 K array-CGH [33]. The 20q11.21 amplification was
described by many authors [4,5,12,21,33,40].
By using array-CGH with a mean resolution of 50 Kb,
we failed to detect any significant effect of the passaging
method used on hESC genomic instability when com-
paring manual/mechanical versus enzymatic/collagenase
IV methods. However, it cannot be excluded that gen-
omic instability below 50 Kb could have occurred. This
could have been detected by other sensitive methods
such as deep genomic sequencing. To our knowledge,
published data are still controversial. Caisander and col-
league used in their retrospective study karyotype, fluor-
escent in situ hybridization (FISH) and classic CGH on
five hESC lines (SA002, SA002.5, AS034.1.1, SA121 and
SA461) after prolonged in vitro culture [16]. When using
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mechanical cell dissociation method, the authors con-
cluded on chromosomal integrity even after two
freeze-thaw procedures and 148 passages of cell cul-
ture. Catalina study in 2009 used conventional karyo-
type, spectral karyotyping (SKY), interphase FISH and
classic CGH on two hESC lines (HS181, HS293) [17].
The authors concluded on an overall genomic stability
whilst maintaining hESC properties (typical morphology,
transcription factors and markers expression associated to
undifferentiated status and in vitro/in vivo pluripotency).
However, mechanical cell dissection combined or not with
enzymatic methods may affect cell growth [10,41-44].
During manual passages, colonies are cut into small pieces
related to their morphology in contrast to enzymatic
methods. However, enzymatic passaging is more efficient
in generating sufficient numbers of undifferentiated cells.
An important issue is to evaluate if the genomic
alteration and the recurrent genomic variations, which
appeared in hESC after repeated passages (with manual
or enzymatic techniques) have a strong impact on their
differentiation and in tumorigenesis potentials. For this
purpose we generated 4 teratomas with hESC picked at
early passages. We were able to show that the tested
hESCs H1 and H9 had the capacity to develop a
complete teratoma displaying tissue from all three germ
layers. In addition, we did not find any malignant tissue
within the teratoma demonstrating that all the observed
genomic variations have no impact on the development
of malignancy. We also performed a Ki-1 antigen (CD30)
immunostaining that was shown previously to be highly
predictive of pluripotent stem cells-derived malignancies
[23]. All teratomas were negative for CD30 confirming the
absence of any embryonic malignant tissues.
Conclusions
In conclusion, based on our observations we can advo-
cate the utilization of collagenase IV for hESC in vitro
culture cell dissociation, a less time-consuming method,
compared to the manual passaging method. Indeed,
there is no difference on cell genomic integrity at early
passages (<p60). Furthermore, regardless of the dissoci-
ation protocol used, teratoma formation was not associated
with embryonic malignant tissues. Our study also showed
9 recurrent copy number variations occurring in hESC
culture including the well-known duplication 20q11.21.
Methods
Human Embryonic Stem Cell (hESC) lines and culture
All the experiments were approved by the French
Biomedical Agency and conducted under the agreement
# RE07-008R. Human embryonic stem cell lines H1 and
H9 derived from 46,XY and 46,XX embryos, respectively
(Wicell Research Institute, http://www.wicell.org) were
maintained into undifferentiated state by continuous
culture on a feeder layer of mitomycin C inactivated
mouse embryonic fibroblasts in DMEM/F12 supplemented
with 20% Knock Out Serum Replacer, 1 mM L-glutamine,
0.5% penicillin/streptomycin, 100 μM 2-mercaptoethanol
and 10 ng/ml basic FGF (all of them from Invitrogen,
Saint-Aubin, France). Cells were weekly passaged by a
mechanical method using a 190–210 μm glass pipette
(Stem cell cutting tool, Swemed, Bayonne, France) under a
stereomicroscope (Lynx, Fisher Bioblock, Strasbourg,
France) or by an enzymatic treatment followed by
mechanical dissociation (“enzymatic method”). Manual
techniques were not performed beyond 60/65 passages.
The enzymatic passaging was carried out by incubating
the cells in 1 mg/ml collagenase IV in DMEM/F12
(Invitrogen, Saint-Aubin, France) during 90 min at 37°C
and 5% CO2. Colonies were then collected and pelleted by
gravity. After two cycles of washing/sedimentation with
DMEM/F12 alone, colonies were mechanically disrupted
by 10 times pipetting with a 1 ml micropipette. Additional
file 2: Table S5 summarized the passages at which further
analysis were realized.
Flow cytometry
Undifferentiated hESC colonies were recovered from
the MEF by incubation in 1 mg/ml collagenase IV in
DMEM/F12 followed by two washes in phosphate buffer
saline (Invitrogen, Saint-Aubin, France). Before staining,
recovered colonies were incubated in Hank’s based en-
zyme free cell dissociation buffer (Invitrogen, Saint-
Aubin, France) 10 min at 37°C and dissociated to the
single cell level by 10 times pipetting with a 1 ml micro-
pipette. Cells were stained using FlowCellect Human ESC
(HESCA-1, SSEA-4) Surface Marker Characterization kit
(Millipore, Molsheim, France) or PE-conjugated mouse
anti-human TRA 1–60 (clone TRA 1–60, BD Biosciences,
Le Pont de Claix, France) according to manufacturer’s in-
structions and analyzed on a MACSQuant flow cytometer
(Miltenyi Biotec, Paris, France) with MACSQuantify
software (Miltenyi Biotec, Paris, France).
Conventional cytogenetic analysis
Chromosome analyses by standard karyotype were per-
formed from 30 cultured cells using standard procedures
(R-bands by heating using Giemsa or RHG, and G-bands
by trypsin using Giemsa or GTG bandings) at regular
passages. The passage number listed represents the total
passage number of the cell line at the time of analysis.
For mitotic preparations, cells were cultured in DMEM/
F12 supplemented with 0.02 mg/ml colchicin (Eurobio,
Courtaboeuf, France) for up to 1 h and 45 min. The cells
were harvested and warm hypotonic solution of 0.075 M
KCl was added in the preparation for up to 15–20 min.
Finally, the cells were fixed several times in cold
Carnoy’s fixative (methanol/acetic acid, 3:1).
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Fluorescent in situ hybridization (FISH)
FISH analyses were performed on 100 interphasic nuclei
and 20 metaphase spreads from H1 and H9 cell lines at
regular passages. The centromeric probes specific for
chromosome 12 and 17 were used according to manu-
facturer’s recommendations (Vysis, Downers Grove, IL).
BAC clones specific for the 20q11.2 chromosomal region
(RP5-1018D12 and RP3-324O17) were used (Bluegnome,
Cambridge, UK).
DNA extraction
Genomic DNA from the two hESC lines was isolated using
a DNeasy Blood and Tissu Kit (Qiagen, Courtaboeuf,
France). The extracted DNA concentrations were esti-
mated using a NanoDrop ND-1 000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA). Ex-
tracted DNA was used for array-CGH.
Oligonucleotide array-comparative genomic hybridization
(array-CGH)
The genomic imbalances of the two hESC lines were an-
alyzed by array-CGH using 105 K oligonucleotide arrays
(Hu-105A Agilent Technologies, Massy, France) at early
manual passages (<60 passages; H1p56, H9p30), at early
enzymatic passages (<60 passages; H1p56, H9p30) and
at late enzymatic passages (>60 passages; H1p159,
H9p87). The passage number listed represents the total
passage number of the cell line at the time of analysis.
All array hybridizations were performed according to
the manufacturer’s recommended protocols. Briefly, 2 μg
of genomic DNA were digested with AluI (5 units) and
RsaI (5 units) for 2 h at 37°C and fluorescently labeled
with the Agilent Genomic DNA labeling kit PLUS (Agilent
Technologies, Massy, France). Male or female human gen-
omic DNA (Promega, Charbonnière, France) was used as
reference. Experiments were done in dye-swap. Cy5-dUTP
cell line DNA and gender-matched reference DNA labeled
with Cy3-dUTP were denatured and preannealed with
Cot-1 DNA and Agilent blocking reagent prior to
hybridization for 40 h at 20 rpm in a 65°C rotating
hybridization oven (Agilent Technologies, Massy, France).
After washing, the slides were scanned on an Agilent
Microarray Scanner. Captured images were processed with
Feature Extraction 9.1 software and data analysis was per-
formed with DEVA software v1.0.2 (Roche Nimblegen,
Meylan, France). The Nexus Copy Number Standard edi-
tion software (Proteigene, Saint-Marcel, France) algorithm
was used for statistical analysis according to the version 18
of the Human genome built (http://genome.ucsc.edu/).
CNV were considered significant if they were defined by 3
or more oligonucleotides spanned at least 50 Kb. The
detection limit for mosaicism rate was arround 10% as
recommended and previously described [45].
Teratoma formation and immunohistochemistry
The teratoma assay was performed with hESC lines (H1
and H9) by intra-muscular injection of 2 to 3×106 of
cells into 6-week-old NOD/SCID mice (Charles River
Laboratories). H1 cells were injected after 44 and 63
passages performed by mechanical or enzymatic dissoci-
ation respectively. H9 cells were injected after 38 and 40
passages performed by mechanical or enzymatic dissoci-
ation respectively. After 96 to 160 days, the teratomas
were dissected and fixed in 4% paraformaldehyde and
samples were embedded in paraffin and stained with
hematoxylin and eosin in order to assess the presence of
ectodermic, endodermic and mesodermic tissues or the
presence of malignant tissue. Immunohistochemistry
was performed as requested with a Benchmark XT ap-
paratus (Ventana, France) with prediluted primary anti-
bodies raised against AE1/AE3 (anti-pan-cytokeratin, BD
Biosciences, France), and Ki-1 antigen CD30 (Ventana).
To evaluate the intensity of CD30-positive areas, an
image of the whole teratoma was taken with a digital
camera (PCO, Germany) and analyzed by the patholo-
gist. For each histological image, CD30-positive areas
and the total surface of the teratoma were manually
selected under Adobe Photoshop. The CD30 expression
was analyzed in extracts of the different teratomas by
using Western blot analysis, as previously described [46].
Briefly, 40 μg of protein was loaded in each well, and the
nitrocellulose membrane was probed with goat anti-
CD30 antibody (1:200 Santa cruz-1737). Goat anti-rabbit
peroxidase-linked antibody (1:10,000; Promega) was used
as a secondary antibody. Actin was detected with monoclo-
nal anti-actin peroxidase conjugated antibody (1:25,000;
Sigma-Aldrich).
Statistical analysis
All array-CGH experimental data are presented as mean ±
SEM. The t-test relative frequencies for independent
variables were used to test the differences. Statistical
analysis was performed using BiostaTGV online soft-
ware (http://marne.u707.jussieu.fr/biostatgv/). We com-
pared i. early manual passages versus early enzymatic
passages ii. early enzymatic passages versus late enzym-
atic passages. The differences were assumed to be sig-
nificant when P-value <0.05.
Additional files
Additional file 1: Figure S1. Pluripotency markers expression. Flow
cytometric analysis of HESCA1, SSEA-4 and TRA 1-60 pluripotency markers
expression by H1 at passages 61 (A) and 139 (B), H9 at passages 35 (C)
and 69 (D).
Additional file 2: Table S5. Passage number at which analysis were done
in hESC lines H1 and H9. List of the passage number using either manual or
enzymatic (collagenase IV) methods at with flow cytometry, karyotype,
array-CGH and teratoma analysis were realized of the hESC lines H1 and H9.
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Additional file 3: Figure S2. Conventional cytogenetic analysis. A.
G-banded karyotype of H1 hESC line at passage 64 showing a normal male
karyotype 46,XY. B. G-banded karyotype of H9 hESC line at passage 59
showing a normal female karyotype 46,XX.
Additional file 4: Figure S3. Chromosome 1 profile from array-CGH
analysis showing recurrent variation on 1q21.3 region. Profiles are illustrated
for H1p56 (a; early and manual passage), H1p159 (b; late and enzymatic
passage), H9p30 (c; early and manual passage) and H9p87 (d; late and
enzymatic passage). For each sample, whole chromosome 1 profile showing
the interstitial variation is presented on the left panel; and the 1q21.3
deletion (a and b) or duplication (c and d) is zoomed in the right panel.
Additional file 5: Table S1. Genes related to development. List of
genes related to development located in genomic variations
corresponding to Figure 3B. Chromosomal position, gene symbol and
encoded protein are noted. G, gain; L, loss.
Additional file 6: Table S2. Genes related to cell cycle, growth and
apoptosis. List of genes related to cell cycle, growth or apoptosis located
in genomic variations corresponding to Figure 3B. Chromosomal position,
gene symbol and encoded protein are noted. G, gain; L, loss.
Additional file 7: Table S3. Genes related to tumorigenesis. List of
genes related to tumorigenesis located in genomic variations
corresponding to Figures 3B and 3C. Chromosomal position, gene
symbol and encoded protein are noted. G, gain; L, loss.
Additional file 8: Table S4. Genes related to syndrome and disease.
List of genes related to syndrome or human disease located in genomic
variations corresponding to Figure 3B. Chromosomal position, gene
symbol and encoded protein are noted. G, gain; L, loss.
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